Erasca vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Erasca Inc (ERAS)

Q3 202627 Jun – 3 Aug 2026

▲2▼1

Erasca's Promising Data and $550M Raise Offset Lawsuit Overhang

Promising ERAS-0015 Phase 1 Data Erasca reported updated Phase 1 data showing ERAS-0015 shrank tumors in 57% of pancreatic cancer patients at the recommended dose. This could boost the stock if it leads to approvals.
This is a new positive clinical development that could drive the stock higher.
$550 Million Stock Offering Erasca raised $550 million in an upsized stock offering at $17.50 per share, easing financial worries and funding research. However, it dilutes existing shareholders.
This is a new capital raise that strengthens the balance sheet but dilutes shareholders.
Securities Class Action Deadline Reminders Six law firms issued reminders about the August 10 lead-plaintiff deadline in the securities class action over ERAS-0015 disclosures. This keeps a negative overhang on ERAS and can weigh on investor sentiment.
This is a new development in the ongoing lawsuit that could pressure the stock.

July 202627 Jun – 3 Aug 2026

▲2▼1

Erasca's Promising Data and $550M Raise Offset Lawsuit Overhang

Promising ERAS-0015 Phase 1 Data Erasca reported updated Phase 1 data showing ERAS-0015 shrank tumors in 57% of pancreatic cancer patients at the recommended dose. This could boost the stock if it leads to approvals.
This is a new positive clinical development that could drive the stock higher.
$550 Million Stock Offering Erasca raised $550 million in an upsized stock offering at $17.50 per share, easing financial worries and funding research. However, it dilutes existing shareholders.
This is a new capital raise that strengthens the balance sheet but dilutes shareholders.
Securities Class Action Deadline Reminders Six law firms issued reminders about the August 10 lead-plaintiff deadline in the securities class action over ERAS-0015 disclosures. This keeps a negative overhang on ERAS and can weigh on investor sentiment.
This is a new development in the ongoing lawsuit that could pressure the stock.

Latest21 Jul – 3 Aug 2026

▼1

Law firm ads keep Erasca's old lawsuit in view as deadline nears

August 10 lead-plaintiff deadline drives fresh lawsuit reminders Six law firms put out notices this period reminding investors of the August 10 deadline to join the securities class action over ERAS-0015 disclosures. The lawsuit itself and the April stock crash it describes are old news; what is new is the deadline publicity, which keeps a negative overhang on ERAS and can weigh on sentiment.
It is the only genuinely new development this period and explains why ERAS is in the news now.

27 Jun – 14 Jul 2026

▲2

Erasca raises $550M and shows 57% response, but lawsuits linger

Updated Phase 1 data shows strong response Erasca reported that ERAS-0015 shrank tumors in 57% of pancreatic cancer patients at the recommended dose. This early but promising result suggests the drug may work, which could boost the stock if it leads to approvals.
This is the key new clinical update that could drive future value and investor optimism.
Upsized $550M offering secures funding Erasca priced a larger-than-expected $550 million stock sale at $17.50 per share. The cash will fund research and trials, easing financial worries, though it dilutes existing shareholders.
This is a major new capital event that directly affects the company's finances and share count.

Q2 202617 Jun – 25 Jun 2026

▼1

Erasca Hit by Wave of Securities Class Actions Over ERAS-0015 Disclosures

Multiple securities class actions filed At least five law firms filed or reminded investors of class actions against Erasca, alleging it misled investors about ERAS-0015's preclinical data and patent risks. These lawsuits create legal costs, management distraction, and potential damages, weighing on the stock.
This is the main new development this period and directly explains negative pressure on ERAS shares.

June 202617 Jun – 25 Jun 2026

▼1

Erasca Hit by Wave of Securities Class Actions Over ERAS-0015 Disclosures

Multiple securities class actions filed At least five law firms filed or reminded investors of class actions against Erasca, alleging it misled investors about ERAS-0015's preclinical data and patent risks. These lawsuits create legal costs, management distraction, and potential damages, weighing on the stock.
This is the main new development this period and directly explains negative pressure on ERAS shares.

17 Jun – 25 Jun 2026

▼1

Erasca Hit by Wave of Securities Class Actions Over ERAS-0015 Disclosures

Multiple securities class actions filed At least five law firms filed or reminded investors of class actions against Erasca, alleging it misled investors about ERAS-0015's preclinical data and patent risks. These lawsuits create legal costs, management distraction, and potential damages, weighing on the stock.
This is the main new development this period and directly explains negative pressure on ERAS shares.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.